Contrasting Synaptogenix (TAOX) & Its Competitors

Synaptogenix (NASDAQ:TAOX) is one of 450 public companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its rivals? We will compare Synaptogenix to related businesses based on the strength of its dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Analyst Ratings

This is a summary of recent recommendations for Synaptogenix and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1	0	0	0	1.00
Synaptogenix Competitors	4780	9954	15974	366	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 77.48%. Given Synaptogenix’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Synaptogenix has less favorable growth aspects than its rivals.

Risk and Volatility

Synaptogenix has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500. Comparatively, Synaptogenix’s rivals have a beta of 10.34, indicating that their average share price is 934% more volatile than the S&P 500.

Profitability

This table compares Synaptogenix and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-277.76%	-150.79%
Synaptogenix Competitors	-2,625.49%	-359.63%	-43.39%

Earnings and Valuation

This table compares Synaptogenix and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Synaptogenix	N/A	-$12.77 million	-0.47
Synaptogenix Competitors	$440.93 million	-$69.09 million	-9.16

Synaptogenix’s rivals have higher revenue, but lower earnings than Synaptogenix. Synaptogenix is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Synaptogenix rivals beat Synaptogenix on 9 of the 13 factors compared.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.